PaxVax, founded in 2007, is an American specialty vaccine company with its headquarters in Redwood City, California. In 2014 the life sciences firm acquired PaxVax Berna in Thörishaus in the Canton of Bern. As a result of this purchase the company more than doubled its size and commercialized its first product (the oral typhoid vaccine Vivotif®). The CEO and President of PaxVax, Nima Farzan, was delighted about how great Switzerland presents itself for growing a company. The local workforce is extraordinary, he adds: «They have excellent technical skills.
Monday, November 30, 2015
for protection wherever you are and wherever you go
PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.